Coherus Oncology, Inc. (CHRS)
About Coherus Oncology, Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $0
- Net income
- $168.0M
- Total assets
- $258.3M
- Market cap
- $223.7M
- Gross margin
- 67.2%
- Operating margin
- -429.5%
- Net margin
- 398.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $42.2M
- Cost of revenue
- $13.8M
- Gross profit
- $28.4M
- Operating expenses
- $209.5M
- Operating income
- -$181.1M
- Income tax
- $0
- Net income
- $168.0M
- EPS (basic)
- $1.43
- EPS (diluted)
- $1.43
Balance sheet
- Total assets
- $258.3M
- Current assets
- $206.7M
- Total liabilities
- $197.3M
- Current liabilities
- $140.4M
- Shareholders’ equity
- $61.0M
Cash flow
- Operating cash flow
- -$138.5M
- Investing cash flow
- $375.1M
- Financing cash flow
- -$273.7M
- Net cash flow
- -$37.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $223.7M
- P/E ratio
- 1.0
- EPS (diluted)
- $1.43
- Shares outstanding
- 158.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2014
Coherus Oncology, Inc. (CHRS) Stock Price
- Profitable — net income of $168.0M in FY2018.
- Revenue declined 87% from FY2021 to FY2025.
- Gross margin of 67.2%, net margin 398.4%.
- Trading 44% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Coherus Oncology, Inc..
Write a review
News about Coherus Oncology, Inc.
News & sentiment via Polygon.io
Coherus Oncology, Inc.: frequently asked questions
Is Coherus Oncology, Inc. an American company?
Coherus Oncology, Inc. is a US-based company headquartered in Redwood City, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Coherus Oncology, Inc. headquartered?
Coherus Oncology, Inc. is headquartered in Redwood City, California, United States.
Is Coherus Oncology, Inc. publicly traded?
Yes — Coherus Oncology, Inc. is a publicly traded company. Its stock trades under the ticker symbol CHRS on the NASDAQ.
What does Coherus Oncology, Inc. do?
Coherus Oncology, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
